FIA
SCPH

FNY Investment Advisers’s scPharmaceuticals SCPH Stock Holding History

FNY Investment Advisers’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,500
Closed -$154K – 706
2022
Q4 		$154K Buy
+21,500
New +$131K 0.22% 99

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

FNY Investment Advisers's SCPH Position: Q1 2023 in Review

FNY Investment Advisers sold out of scPharmaceuticals (SCPH) in Q1 2023, closing a stake of 21,500 shares — an estimated $154K sold.

FNY Investment Advisers first reported a position in SCPH in Q4 2022 and held it in 1 quarter. The position peaked at $154K in Q4 2022. 62 funds tracked by Wall St. Rank hold SCPH as of Q1 2023.

  • FNY Investment Advisers reported no remaining scPharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 21,500 scPharmaceuticals shares in Q1 2023, an estimated $154K.
  • FNY Investment Advisers first reported a position in scPharmaceuticals in Q4 2022 and held it in 1 quarter.
  • FNY Investment Advisers's scPharmaceuticals position peaked at $154K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2023.

Based on FNY Investment Advisers's 13F filing for Q1 2023, filed 12 Apr 2023.